Research graph
References from Sunitinib in Patients With Various Solid Tumors With FGFR1 / 2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/s41571-024-00869-z
10.1038/s41571-024-00869-z · External reference
10.1038/s41392-020-00222-7
10.1038/s41392-020-00222-7 · External reference
10.4161/cc.8.4.7657
10.4161/cc.8.4.7657 · External reference
10.1200/jco.2020.38.15_suppl.3620
10.1200/jco.2020.38.15_suppl.3620 · External reference
10.1158/1078-0432.ccr-14-3212
10.1158/1078-0432.ccr-14-3212 · External reference
10.21037/atm-20-5118
10.21037/atm-20-5118 · External reference
10.1186/s13045-024-01558-1
10.1186/s13045-024-01558-1 · External reference
10.1056/nejmoa2308849
10.1056/nejmoa2308849 · External reference
10.1056/evidoa2500017
10.1056/evidoa2500017 · External reference
10.1016/j.esmoop.2024.103488
10.1016/j.esmoop.2024.103488 · External reference
10.1056/nejmoa2206834
10.1056/nejmoa2206834 · External reference
Phase II study of erdafitinib in patients with tumors with FGFR amplifications: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol K1
External reference
Phase II study of erdafitinib in patients with tumors with fibroblast growth factor receptor mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol K2
External reference
Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies: A pooled analysis of early-phase clinical trials
External reference
10.1016/j.esmoop.2024.103625
10.1016/j.esmoop.2024.103625 · External reference
10.1016/j.annonc.2022.02.001
10.1016/j.annonc.2022.02.001 · External reference
10.1093/annonc/mdw435.22
10.1093/annonc/mdw435.22 · External reference
10.1056/nejmoa1003825
10.1056/nejmoa1003825 · External reference
10.1016/s0140-6736(06)69446-4
10.1016/s0140-6736(06)69446-4 · External reference
10.1056/nejmoa1611406
10.1056/nejmoa1611406 · External reference
10.1056/nejmoa065044
10.1056/nejmoa065044 · External reference
Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the Targeted Agent and Profiling Utilization Registry study
External reference
10.1016/j.clgc.2018.11.002
10.1016/j.clgc.2018.11.002 · External reference
Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study
External reference
Palbociclib in patients with head and neck cancer and other tumors with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study
External reference
Olaparib in patients with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
External reference
Olaparib in patients with solid tumors with BRCA1/2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
External reference
Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the Targeted Agent and Profiling Utilization Registry study
External reference
Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2/3 amplification, overexpression, or mutation: Results from the TAPUR study
External reference
Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the Targeted Agent and Profiling Utilization Registry Study
External reference
10.1016/j.esmoop.2025.104545
10.1016/j.esmoop.2025.104545 · External reference
Talazoparib in patients with solid tumors with BRCA1/2 mutation: Results from the Targeted Agent and Profiling Utilization Registry study
External reference
10.1200/jco.23.02078
10.1200/jco.23.02078 · External reference
Regorafenib in patients with solid tumors with BRAF alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
External reference
Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
External reference
Olaparib in patients with pancreatic cancer with BRCA1/2 mutations: Results from the Targeted Agent and Profiling Utilization Registry study
External reference
Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry study
External reference
Palbociclib in patients with Non–small-cell lung cancer with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study
External reference
Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry study
External reference
10.1200/jco.23.00702
10.1200/jco.23.00702 · External reference
Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
External reference
Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2/3 mutations: Results from the TAPUR study
External reference
Olaparib in patients with metastatic prostate cancer with BRCA1/2 mutation: Results from the TAPUR study
External reference
10.1200/jco.20.02923
10.1200/jco.20.02923 · External reference
10.1007/s11523-020-00753-7
10.1007/s11523-020-00753-7 · External reference
10.1007/s11523-020-00752-8
10.1007/s11523-020-00752-8 · External reference
10.1016/j.ejca.2008.10.026
10.1016/j.ejca.2008.10.026 · External reference
10.1200/jco.2017.75.5009
10.1200/jco.2017.75.5009 · External reference
10.1016/s2468-1253(21)00196-5
10.1016/s2468-1253(21)00196-5 · External reference
10.1016/j.annonc.2020.06.018
10.1016/j.annonc.2020.06.018 · External reference
10.1016/s1470-2045(23)00275-9
10.1016/s1470-2045(23)00275-9 · External reference
Erdafitinib or erdafitinib plus cetrelimab for patients with metastatic urothelial carcinoma and FGFR alterations: Final results from the phase II NORSE study
2023 · External reference
10.1158/2159-8290.cd-21-0697
10.1158/2159-8290.cd-21-0697 · External reference
10.1038/nrc.2017.8
10.1038/nrc.2017.8 · External reference
10.1038/s41416-020-01157-0
10.1038/s41416-020-01157-0 · External reference
OncoKB: A precision oncology knowledge base
External reference
10.1158/2159-8290.cd-23-0467
10.1158/2159-8290.cd-23-0467 · External reference
10.1038/s41586-022-05066-5
10.1038/s41586-022-05066-5 · External reference
10.1158/0008-5472.can-09-3746
10.1158/0008-5472.can-09-3746 · External reference
10.1186/bcr1665
10.1186/bcr1665 · External reference
10.1200/jco.2012.43.8622
10.1200/jco.2012.43.8622 · External reference
10.18632/oncotarget.2944
10.18632/oncotarget.2944 · External reference
10.1016/j.cllc.2018.09.001
10.1016/j.cllc.2018.09.001 · External reference
10.1158/1078-0432.ccr-24-3803
10.1158/1078-0432.ccr-24-3803 · External reference
10.1093/annonc/mdx107
10.1093/annonc/mdx107 · External reference
10.1200/jco.19.02630
10.1200/jco.19.02630 · External reference
10.1038/s41467-022-30666-0
10.1038/s41467-022-30666-0 · External reference
10.1158/1078-0432.ccr-17-0478
10.1158/1078-0432.ccr-17-0478 · External reference
10.1016/j.jhep.2023.10.041
10.1016/j.jhep.2023.10.041 · External reference
10.1038/sj.bjc.6604456
10.1038/sj.bjc.6604456 · External reference
10.1200/jco.2007.14.5375
10.1200/jco.2007.14.5375 · External reference
10.1093/neuonc/nou148
10.1093/neuonc/nou148 · External reference
10.1038/bjc.2015.196
10.1038/bjc.2015.196 · External reference
